A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinoma

Nan Lin, Yongping Lin, Jianfeng Xu, Dan Liu, Diange Li, Hongyu Meng, Maxime A. Gallant, Naoto Kubota, Dhruvajyoti Roy, Jason S. Li, Emmanuel C. Gorospe, Morris Sherman, Robert G. Gish, Ghassan K. Abou‐Alfa, Mindie H. Nguyen, David J. Taggart, Richard A. Van Etten, Yujin Hoshida, Wei Li – 2 March 2022 – The limited performance of guideline‐recommended abdominal ultrasound and serum alpha‐fetoprotein (AFP) highlights the urgent, unmet need for new biomarkers for more accurate detection of early hepatocellular carcinoma (HCC).

Diabetes medications and risk of HCC

Maria Corina Plaz Torres, Ariel Jaffe, Rachel Perry, Elisa Marabotto, Mario Strazzabosco, Edoardo G. Giannini – 2 March 2022 – Type 2 diabetes mellitus is a recognized risk factor for HCC in patients with liver disease, independent from the etiology of their liver disease. Hence, prevention and treatment of type 2 diabetes mellitus and its underlying cause, insulin resistance, should be considered a treatment target for patients with liver disease.

Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies

Rosyli F. Reveron‐Thornton, Margaret L. P. Teng, Eunice Yewon Lee, Andrew Tran, Sean Vajanaphanich, Eunice X. Tan, Sanjna N. Nerurkar, Rui Xin Ng, Readon Teh, Debi Prasad Tripathy, Takanori Ito, Taku Tanaka, Nozomi Miyake, Biyao Zou, Connie Wong, Hidenori Toyoda, Carlos O. Esquivel, C. Andrew Bonham, Mindie H. Nguyen, Daniel Q. Huang – 1 March 2022 – Surgical resection for HCC remains a major curative treatment option, but it is unclear whether there are differences in outcomes by region and whether outcomes have improved over time.

Anonymity: What does it mean and why is it important to anonymous living liver donors?

Sapna Humar, Judy Jung, Sandra Krause, Nazia Selzner, Susan Abbey – 28 February 2022 – Anonymous living organ donation has recently become more common in select transplantation programs, with donors voluntarily offering a kidney or a lobe of their liver to those in need. These anonymous donations may be directed to a specific recipient or nondirected, and anonymity may be one way or reciprocal. Given their unique situation, we interviewed a cohort of anonymous living liver donors and explored their opinions surrounding anonymity and its implications in living liver donation.

Cholestatic liver diseases of genetic etiology: Advances and controversies

Samar H. Ibrahim, Binita M. Kamath, Kathleen M. Loomes, Saul J. Karpen – 28 February 2022 – With the application of modern investigative technologies, cholestatic liver diseases of genetic etiology are increasingly identified as the root cause of previously designated “idiopathic” adult and pediatric liver diseases. Here, we review advances in the field enhanced by a deeper understanding of the phenotypes associated with specific gene defects that lead to cholestatic liver diseases.

Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation

Lydia Sastre, Raquel García, Clara Viñals, Antonio J. Amor, Gema Yago, Alicia Hervás, Lorena Sánchez, Joan Trabal, Judit Molero, Laia Escudé, Giulia Pagano, Miquel Blasco, Rosa Gilabert, Pablo Ruiz, Jordi Colmenero, Miquel Navasa, Emilio Ortega, Gonzalo Crespo – 27 February 2022 – Although liver transplantation (LT) recipients are at high cardiovascular risk (CVR), the management of CVR factors (CVRF) after LT is far from optimal and needs to be improved.

Subscribe to